Structural and dynamic control of T-cell receptor specificity, cross-reactivity, and binding mechanism

Immunological Reviews

Volumn 250, Issue 1, 2012, Pages 10-31

  Baker, Brian M ^a   Scott, Daniel R ^a   Blevins, Sydney J ^a   Hawse, William F ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

Cross reactivity; MHC; Molecular flexibility; Specificity; Structure; T cell receptor

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN; MELAN A; MELANOMA VACCINE; PEPTIDE VACCINE; T LYMPHOCYTE RECEPTOR;

ALPHA HELIX; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CANCER IMMUNIZATION; CROSS REACTION; DRUG DESIGN; HUMAN; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MIMICRY; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STRUCTURE; RECEPTOR BINDING;

ANIMALS; ANTIGENS; BINDING SITES; CROSS REACTIONS; HUMANS; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; MODELS, MOLECULAR; PEPTIDES; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, ANTIGEN, T-CELL; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES;

EID: 84867426149     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2012.01165.x     Document Type: Article

References (134)

1. Stern LJ, et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994;368:215-221.
2. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987;329:506-512.
3. Garboczi DN, Ghosh P, Utz U, Fan QR, Biddison WE, Wiley DC. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 1996;384:134-141.
4. Garcia KC, et al. An alphabeta T cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex. Science 1996;274:209-219.
5. Zinkernagel RM, Doherty PC. Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytes choriomeningitis. Nature 1974;251:547-548.
6. Braden BC, Goldman ER, Mariuzza RA, Poljak RJ. Anatomy of an antibody molecule: structure, kinetics, thermodynamics and mutational studies of the antilysozyme antibody D1.3. Immunol Rev 1998;163:45-57.
7. Wilson IA, Stanfield RL. Antibody-antigen interactions. Curr Opin Struct Biol 1993;3:113-118.
8. Mason D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today 1998;19:395-404.
9. Garcia KC, et al. Structural basis of plasticity in T cell receptor recognition of a self peptide-MHC antigen. Science 1998;279:1166-1172.
10. Utz U, Banks D, Jacobson S, Biddison WE. Analysis of the T-cell receptor repertoire of human T-cell leukemia virus type 1 (HTLV-1) Tax-specific CD8+ cytotoxic T lymphocytes from patients with HTLV-1-associated disease: evidence for oligoclonal expansion. J Virol 1996;70:843-851.
11. Hausmann S, et al. Peptide recognition by two HLA-A2/Ta11-19-specific T cell clones in relationship to their MHC/peptide/TCR crystal structures. J Immunol 1999;162:5389-5397.
12. Ding YH, Baker BM, Garboczi DN, Biddison WE, Wiley DC. Four A6-TCR/peptide/HLA-A2 structures that generate very different T cell signals are nearly identical. Immunity 1999;11:45-56.
13. Baker BM, Gagnon SJ, Biddison WE, Wiley DC. Conversion of a T cell antagonist into an agonist by repairing a defect in the TCR/Peptide/MHC interface. Implications for TCR Signaling. Immunity 2000;13:475-484.
14. Mazza C, et al. How much can a T-cell antigen receptor adapt to structurally distinct antigenic peptides? EMBO J 2007;26:1972-1983.
15. Reiser JB, et al. A T cell receptor CDR3beta loop undergoes conformational changes of unprecedented magnitude upon binding to a peptide/MHC class I complex. Immunity 2002;16:345-354.
16. Reiser JB, et al. CDR3 loop flexibility contributes to the degeneracy of TCR recognition. Nat Immunol 2003;4:241-247.
17. Tynan FE, et al. A T cell receptor flattens a bulged antigenic peptide presented by a major histocompatibility complex class I molecule. Nat Immunol 2007;8:268-276.
18. Chen J-L, et al. Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J Exp Med 2005;201:1243-1255.
19. Lee JK, et al. T Cell Cross-Reactivity and Conformational Changes during TCR Engagement. J Exp Med 2004;200:1455-1466.
20. Burrows SR, et al. Hard wiring of T cell receptor specificity for the major histocompatibility complex is underpinned by TCR adaptability. Proc Natl Acad Sci USA 2010;107:10608-10613.
21. Gagnon SJ, et al. Unraveling a hotspot for TCR Recognition on HLA-A2: evidence against the existence of peptide-independent TCR binding determinants. J Mol Biol 2005;353:556-573.
22. Baker BM, Turner RV, Gagnon SJ, Wiley DC, Biddison WE. Identification of a crucial energetic footprint on the α1 helix of human histocompatibility leukocyte atigen (HLA)-A2 that provides functional interactions for recognition by Tax peptide/HLA-A2-specific T cell receptors. J Exp Med 2001;193:551-562.
23. DeLano WL. Unraveling hot spots in binding interfaces: progress and challenges. Curr Opin Struct Biol 2002;12:14-20.
24. Gagnon SJ, Turner RV, Shiue MG, Damirjian M, Biddison WE. Extensive T cell receptor cross-reactivity on structurally diverse haptenated peptides presented by HLA-A2. Mol Immunol 2006;43:346-356.
25. Gagnon SJ, et al. T cell receptor recognition via cooperative conformational plasticity. J Mol Biol 2006;363:228-243.
26. Scott DR, Borbulevych OY, Piepenbrink KH, Corcelli SA, Baker BM. Disparate degrees of hypervariable loop flexibility control T-cell receptor cross-reactivity, specificity, and binding mechanism. J Mol Biol 2011;414:385-400.
27. Borbulevych OY, Piepenbrink KH, Baker BM. Conformational melding permits a conserved binding geometry in TCR recognition of foreign and self molecular mimics. J Immunol 2011;186:2950-2958.
28. Piepenbrink KH, et al. Fluorine substitutions in an antigenic peptide selectively modulate T-cell receptor binding in a minimally perturbing manner. Biochem J 2009;423:353-361.
29. Borbulevych OY, et al. T cell receptor cross-reactivity directed by antigen-dependent tuning of peptide-MHC molecular flexibility. Immunity 2009;31:885-896.
30. Garcia KC, Adams EJ. How the T cell receptor sees antigen - a structural view. Cell 2005;122:333-336.
31. Yin L, et al. A single T cell receptor bound to major histocompatibility complex class I and Class II glycoproteins reveals switchable TCR conformers. Immunity 2011;35:23-33.
32. McBeth C, et al. A new twist in TCR diversity revealed by a forbidden αβ TCR. J Mol Biol 2008;375:1306-1319.
33. Sundberg EJ, Mariuzza RA. Molecular recognition in antibody-antigen complexes. Adv Protein Chem 2002;61:119-160.
34. Oldstone MBA. Molecular mimicry and immune-mediated diseases. FASEB J 1998;12:1255-1265.
35. Kohm AP, Fuller KG, Miller SD. Mimicking the way to autoimmunity: an evolving theory of sequence and structural homology. Trends Microbiol 2003;11:101-105.
36. Wucherpfennig KW. Structural basis of molecular mimicry. J Autoimmun 2001;16:293-302.
37. Auphan-Anezin N, et al. Distinct orientation of the alloreactive monoclonal CD8 T cell activation program by three different peptide/MHC complexes. Eur J Immunol 2006;36:1856-1866.
38. Li Y, Huang Y, Lue J, Quandt JA, Martin R, Mariuzza RA. Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule. EMBO J 2005;24:2968-2979.
39. Tobi D, Bahar I. Structural changes involved in protein binding correlate with intrinsic motions of proteins in the unbound state. Proc Natl Acad Sci USA 2005;102:18908-18913.
40. Bahar I, Chennubhotla C, Tobi D. Intrinsic dynamics of enzymes in the unbound state and relation to allosteric regulation. Curr Opin Struct Biol 2007;17:633-640.
41. Keskin O. Binding induced conformational changes of proteins correlate with their intrinsic fluctuations: a case study of antibodies. BMC Struct Biol 2007;7:1-11.
42. Pohlmann T, Bockmann RA, Grubmuller H, Uchanska-Ziegler B, Ziegler A, Alexiev U. Differential peptide dynamics is linked to MHC polymorphism. J Biol Chem 2004;279:28197-28201.
43. Narzi D, Becker CM, Fiorillo MT, Uchanska-Ziegler B, Ziegler A, Böckmann RA. Dynamical characterization of two differentially disease associated MHC class I proteins in complex with viral and self-peptides. J Mol Biol 2012;415:429-442.
44. Smith KJ, Reid SW, Stuart DI, McMichael AJ, Jones EY, Bell JI. An altered position of theα2 helix of MHC class I is revealed by the crystal structure of HLA-B*3501. Immunity 1996;4:203-213.
45. Brown D, Trowsdale J, Allen R. The LILR family: modulators of innate and adaptive immune pathways in health and disease. Tissue Antigens 2004;64:215-225.
46. Pegram HJ, Andrews DM, Smyth MJ, Darcy PK, Kershaw MH. Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol 2011;89:216-224.
47. Natarajan K, Dimasi N, Wang J, Mariuzza RA, Margulies DH. Structure and function of antrual killer cell receptors: multiple molecular solutions to self, nonself discrimination. Annu Rev Immunol 2002;20:853-885.
48. Dam J, et al. Variable MHC class I engagement by Ly49 natural killer cell receptors demonstrated by the crystal structure of Ly49C bound to H-2Kb. Nat Immunol 2003;4:1213-1222.
49. Ma BJ, Kane KP. Recognition of class I MHC by a rat Ly49 NK cell receptor is dependent on the identity of the P2 anchor amino acid of bound peptide. J Immunol 2011;187:3267-3276.
50. Stewart-Jones GB, di Gleria K, Kollnberger S, McMichael AJ, Jones EY, Bowness P. Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-B*2705. Eur J Immunol 2005;35:341-351.
51. Vivian JP, et al. Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen B. Nature 2011;479:401-405.
52. Gao GF, et al. Crystal structure of the complex between human CD8alpha (alpha) and HLA- A2. Nature 1997;387:630-634.
53. Wucherpfennig KW, Call MJ, Deng L, Mariuzza R. Structural alterations in peptide-MHC recognition by self-reactive T cell receptors. Curr Opin Immunol 2009;21:590-595.
54. Nicholson MJ, Hahn M, Wucherpfennig KW. Unusual features of self-peptide/MHC binding by autoimmune T cell receptors. Immunity 2005;23:351-360.
55. Yin Y, Li Y, Kerzic MC, Martin R, Mariuzza RA. Structure of a TCR with high affinity for self-antigen reveals basis for escape from negative selection. EMBO J 2011;30:1137-1148.
56. Cole DK, et al. Germline-governed recognition of a cancer epitope by an immunodominant human T-cell receptor. J Biol Chem 2009;284:27281-27289.
57. Borbulevych OY, Santhanagopolan SM, Hossain M, Baker BM. TCRs used in cancer gene therapy cross-react with MART-1/Melan-A Tumor antigens via distinct mechanisms. J Immunol 2011;187:2453-2463.
58. Zerrahn J, Held W, Raulet DH. The MHC reactivity of the T cell repertoire prior to positive and negative selection. Cell 1997;88:627-636.
59. Wu LC, Tuot DS, Lyons DS, Garcia KC, Davis MM. Two-step binding mechanism for T-cell receptor recognition of peptide MHC. Nature 2002;418:552-556.
60. Holler PD, Kranz DM. T cell receptors: affinities, cross-reactivities, and a conformer model. Mol Immunol 2004;40:1027-1031.
61. Boniface JJ, Reich Z, Lyons DS, Davis MM. Thermodynamics of T cell receptor binding to peptide-MHC: evidence for a general mechanism of molecular scanning. Proc Natl Acad Sci USA 1999;96:11446-11451.
62. Csermely P, Palotai R, Nussinov R. Induced fit, conformational selection and independent dynamic segments: an extended view of binding events. Trends Biochem Sci 2010;35:539-546.
63. Boehr DD, Nussinov R, Wright PE. The role of dynamic conformational ensembles in biomolecular recognition. Nat Chem Biol 2009;5:789-796.
64. James LC, Roversi P, Tawfik DS. Antibody multispecificity mediated by conformational diversity. Science 2003;299:1362-1367.
65. James LC, Tawfik DS. Structure and kinetics of a transient antibody binding intermediate reveal a kinetic discrimination mechanism in antigen recognition. Proc Natl Acad Sci USA 2005;102:12730-12735.
66. Foote J, Milstein C. Conformational isomerism and the diversity of antibodies. Proc Natl Acad Sci USA 1994;91:10370-10374.
67. Gakamsky DM, Luescher IF, Pecht I. T cell receptor-ligand interactions: a conformational preequilibrium or an induced fit. Proc Natl Acad Sci USA 2004;101:9063-9066.
68. Pauling L. A theory of the structure and process of formation of antibodies. J Am Chem Soc 1940;62:2643-2657.
69. James LC, Tawfik DS. Conformational diversity and protein evolution-a 60-year-old hypothesis revisited. Trends Biochem Sci 2003;28:361-368.
70. Armstrong KM, Piepenbrink KH, Baker BM. Conformational changes and flexibility in T-cell receptor recognition of peptide-MHC complexes. Biochem J 2008;415:183-196.
71. Hare BJ, Wyss DF, Osburne MS, Kern PS, Reinherz EL, Wagner G. Structure, specificity and CDR mobility of a class II restricted single-chain T-cell receptor. Nat Struct Biol 1999;6:574-581.
72. Davis-Harrison RL, Insaidoo FK, Baker BM. T cell receptor binding transition states and recognition of peptide/MHC. Biochemistry 2007;46:1840-1850.
73. Armstrong KM, Baker BM. A comprehensive calorimetric investigation of an entropically driven T cell receptor-peptide/major histocompatibility complex interaction. Biophys J 2007;93:597-609.
74. Davis-Harrison RL, Armstrong KM, Baker BM. Two different T cell receptors use different thermodynamic strategies to recognize the same peptide/MHC ligand. J Mol Biol 2005;346:533-550.
75. Armstrong KM, Insaidoo FK, Baker BM. Thermodynamics of T-cell receptor-peptide/MHC interactions: progress and opportunities. J Mol Recognit 2008;21:275-287.
76. Gakamsky DM, et al. Kinetic evidence for a ligand-binding-induced conformational transition in the T cell receptor. Proc Natl Acad Sci USA 2007;104:16639-16644.
77. Robinson J, Mistry K, McWilliam H, Lopez R, Parham P, Marsh SG. The IMGT/HLA database. Nucleic Acids Res 2011;39:D1171-D1176.
78. Deng L, et al. Structural basis for the recognition of mutant self by a tumor-specific, MHC class II-restricted T cell receptor. Nat Immunol 2007;8:398-408.
79. Degano M, Garcia KC, Apostolopoulos V, Rudolph MG, Teyton L, Wilson IA. A functional hot spot for antigen recognition in a superagonist TCR/MHC complex. Immunity 2000;12:251-261.
80. Feng D, Bond CJ, Ely LK, Maynard J, Garcia KC. Structural evidence for a germline-encoded T cell receptor-major histocompatibility complex interaction 'codon'. Nat Immunol 2007;8:975-983.
81. Kjer-Nielsen L, et al. A structural basis for the selection of dominant alphabeta T cell receptors in antiviral immunity. Immunity 2003;18:53-64.
82. Fabian H, Loll B, Huser H, Naumann D, Uchanska-Ziegler B, Ziegler A. Influence of inflammation-related changes on conformational characteristics of HLA-B27 subtypes as detected by IR spectroscopy. FEBS J 2011;278:1713-1727.
83. Fabian H, et al. HLA-B27 subtypes differentially associated with disease exhibit conformational differences in solution. J Mol Biol 2008;376:798-810.
84. Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 2007;6:404-414.
85. Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? Immunol Rev 2011;239:27-44.
86. Madden DR. The three-dimensional structure of peptide-MHC complexes. Annu Rev Immunol 1995;13:587-622.
87. Parkhurst M, et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 1996;157:2539-2548.
88. Yu Z, et al. Poor immunogenicity of a self/tumor antigen derives from peptide/MHC-I instability and is independent of tolerance. J Clin Invest 2004;114:551-559.
89. Rosenberg SA, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-327.
90. Borbulevych OY, Baxter TK, Yu Z, Restifo NP, Baker BM. Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design. J Immunol 2005;174:4812-4820.
91. Skipper JCA, et al. Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. Int J Cancer 1999;82:669-677.
92. Borbulevych OY, et al. Structures of MART-1 (26/27-35) peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition. J Mol Biol 2007;372:1123-1136.
93. Derré L, et al. A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide. J Immunol 2007;179:7635-7645.
94. Insaidoo FK, Borbulevych OY, Hossain M, Santhanagopolan SM, Baxter TK, Baker BM. Loss of T cell antigen recognition arising from changes in peptide and major histocompatibility complex protein flexibility. J Biol Chem 2011;286:40163-40173.
95. Kawakami Y, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-352.
96. Rivoltini L, et al. Induction of tumor-reactive CTL from peripheral blood and tumor- infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995;154:2257-2265.
97. Douat-Casassus C, et al. Crystal structures of HLA-A*0201 complexed with Melan-A/MART-1 (26 (27L)-35) peptidomimetics reveal conformational heterogeneity and highlight degeneracy of Tcell recognition. J Med Chem 2010;53:7061-7066.
98. Sliz P, et al. Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes. J Immunol 2001;167:3276-3284.
99. Cole DK, et al. Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition. J Immunol 2010;185:2600-2610.
100. Speiser DE, et al. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci USA 2008;105:3849-3854.
101. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012;12:269-281.
102. Zhang L, Morgan RA. Genetic engineering with T cell receptors. Adv Drug Deliv Rev 2011;64:756-762.
103. Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends Biotechnol 2011;29:550-557.
104. Morgan RA, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-129.
105. Johnson LA, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009;114:535-546.
106. Johnson LA, et al. Gene Transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol 2006;177:6548-6559.
107. Colf LA, et al. How a single T cell receptor recognizes both self and foreign MHC. Cell 2007;129:135-146.
108. Clements CS, Dunstone MA, Macdonald WA, McCluskey J, Rossjohn J. Specificity on a knife-edge: the αβ T cell receptor. Curr Opin Struct Biol 2006;16:787-795.
109. Marrack P, Scott-Browne JP, Dai S, Gapin L, Kappler JW. Evolutionarily conserved amino acids that control TCR-MHC interaction. Annu Rev Immunol 2008;26:171-203.
110. Garcia KC, Adams JJ, Feng D, Ely LK. The molecular basis of TCR germline bias for MHC is surprisingly simple. Nat Immunol 2009;10:143-147.
111. Jerne NK. The somatic generation of immune recognition. Eur J Immunol 1971;1:1-9.
112. Scott-Browne JP, White J, Kappler JW, Gapin L, Marrack P. Germline-encoded amino acids in the [agr][bgr] T-cell receptor control thymic selection. Nature 2009;458:1043-1046.
113. Collins E, Riddle D. TCR-MHC docking orientation: natural selection, or thymic selection? Immunol Res 2008;41:267-294.
114. Van Laethem F, et al. Deletion of CD4 and CD8 coreceptors permits generation of [alpha][beta]T cells that recognize antigens independently of the MHC. Immunity 2007;27:735-750.
115. Tikhonova A, et al. αβ T cell receptors that do not undergo major histocompatibility complex-specific thymic selection possess antibody-like recognition specificities. Immunity 2012;36:79-91.
116. Adams Jarrett J, et al. T cell receptor signaling is limited by docking geometry to peptide-major histocompatibility complex. Immunity 2011;35:681-693.
117. Ding YH, Smith KJ, Garboczi DN, Utz U, Biddison WE, Wiley DC. Two human T cell receptors bind in a similar diagonal mode to the HLA- A2/Tax peptide complex using different TCR amino acids. Immunity 1998;8:403-411.
118. Koide S, Sidhu SS. The importance of being tyrosine: lessons in molecular recognition from minimalist synthetic binding proteins. ACS Chem Biol 2009;4:325-334.
119. Birtalan S, Zhang Y, Fellouse FA, Shao L, Schaefer G, Sidhu SS. The intrinsic contributions of tyrosine, serine, glycine and arginine to the affinity and specificity of antibodies. J Mol Biol 2008;377:1518-1528.
120. Yin Y, Mariuzza RA. The multiple mechanisms of T cell receptor cross-reactivity. Immunity 2009;31:849-851.
121. Kovrigin EL, Loria JP. Enzyme dynamics along the reaction coordinate: critical role of a conserved residue. Biochemistry 2006;45:2636-2647.
122. Mittag T, Schaffhausen B, Günther UL. Tracing kinetic intermediates during ligand binding. J Am Chem Soc 2004;126:9017-9023.
123. Varani L, et al. Solution mapping of T cell receptor docking footprints on peptide-MHC. Proc Natl Acad Sci USA 2007;104:13080-13085.
124. Benesch JLP, Ruotolo BT. Mass spectrometry: come of age for structural and dynamical biology. Curr Opin Struct Biol 2011;21:641-649.
125. Brophy SE, Holler PD, Kranz DM. A yeast display system for engineering functional peptide-MHC complexes. J Immunol Methods 2003;272:235-246.
126. Shusta EV, Holler PD, Kieke MC, Kranz DM, Wittrup KD. Directed evolution of a stable scaffold for T-cell receptor engineering. Nat Biotechnol 2000;18:754-759.
127. Varela-Rohena A, et al. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med 2008;14:1390-1395.
128. Laugel B, et al. Design of soluble recombinant T cell receptors for antigen targeting and T cell inhibition. J Biol Chem 2005;280:1882-1892.
129. Hawse WF, et al. Cutting edge: evidence for a dynamically driven T cell signaling mechanism. J Immunol 2012;188:5819-5823.
130. Irving M, et al. Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J Biol Chem 2012;287:23068-23078.
131. Haidar JN, Pierce B, Yu Y, Tong W, Li M, Weng Z. Structure-based design of a T-cell receptor leads to nearly 100-fold improvement in binding affinity for pepMHC. Proteins: Struct, Funct, Bioinf 2009;74:948-960.
132. Bolon DN, Grant RA, Baker TA, Sauer RT. Specificity versus stability in computational protein design. Proc Natl Acad Sci USA 2005;102:12724-12729.
133. Holler PD, Chlewicki LK, Kranz DM. TCRs with high affinity for foreign pMHC show self-reactivity. Nat Immunol 2003;4:55-62.
134. Zhao Y, et al. High-affinity TCRs generated by phage display provide CD4(+) T cells with the ability to recognize and kill tumor cell lines. J Immunol 2007;179:5845-5854.